Caris Life Sciences, Inc.
CAI- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0002019410
In the last 90 days, Caris Life Sciences, Inc. insiders filed 1 open-market purchase and 3 sales; 247 institutions reported holding it in 13F filings for Q2 2026, worth $2.75B in total; superinvestors Coatue Management and Duquesne Family Office hold it.
Key figures
- Insider buysLast 90 days, $990.1K in total
- 1
- Insider sellsLast 90 days, $27.2M in total
- 3
- 13F holdersQ2 2026, +46 vs. previous quarter
- 247
- 13F valueReported value at the end of Q2 2026
- $2.75B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Superinvestors holding CAI, Q2 2026
2 superinvestors report holding Caris Life Sciences, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Coatue Management
Philippe Laffont
0.4%
Caris Life Sciences, Inc.'s share of the portfolio
- Shares
- 9,819,992
- Value
- $175.0M
Duquesne Family Office
Stanley Druckenmiller
0.8%
Caris Life Sciences, Inc.'s share of the portfolio
- Shares
- 1,894,450
- Value
- $33.8M
Latest insider trades
Open-market purchases and sales by Caris Life Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 (view filing)5:06 PM ET | Sep 22 | 1 day | Denton John RusselSee Remarks | SSale | −7.50K | $31.82 | −$238.6K | −4.1%174.9K after | |
| Sep 17, 2026 (view filing)6:08 PM ET | Sep 17 | Same day | Brille Brian JSee Remarks | SSale | −400.0K | $30.33 | −$12.1M | −63.5%230.3K after | |
| Sep 4, 2026 (view filing)4:59 PM ET | Sep 3-4 | 1 day | Spetzler David BaxleyPresident | SSale | −597.2K | $24.84 | −$14.8M | −33.5%1.18M after | 3 lots |
| Jul 13, 2026 (view filing)7:06 AM ET | May 15 | 59 daysLate | Halbert JonDirector | PPurchase | +68.0K | $14.56 | +$990.1K | +10.7%704.6K after | |
| May 12, 2026 (view filing) | May 11 | 1 day | Vacirca Jeff LDirector | PPurchase | +31.1K | $16.15 | +$501.5K | +166.7%49.7K after | |
| Dec 12, 2025 (view filing) | Dec 11 | 1 day | Power Luke ThomasSee Remarks | SSale | −62.3K | $26.57 | −$1.65M | −38.5%99.6K after | 2 lots10b5-1 |
| Nov 10, 2025 (view filing) | Nov 7 | 3 days | Spetzler David BaxleyPresident | PPurchase | +400 | $23.85 | +$9.54K | +0.1%460.8K after | |
| Nov 10, 2025 (view filing) | Nov 7 | 3 days | Denton John RusselSee Remarks | PPurchase | +4.18K | $24.09 | +$100.8K | +83.7%9.18K after | |
| Jun 23, 2025 (view filing) | Jun 20 | 3 days | Denton John RusselSee Remarks | PPurchase | +7.50K | $21.00 | +$157.5K | +6.5%123.6K after | |
| Jun 23, 2025 (view filing) | Jun 20 | 3 days | Brille Brian JSee Remarks | PPurchase | +30.0K | $21.00 | +$630.0K | +22.7%162.4K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Caris Life Sciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 30,923,878 | $551.1M | 0.02% | +138,293+0.4% | Added |
| J. H. Whitney Equity Partners VI, LLC | 11,256,615 | $200.6M | 100.00% | −7,000,000−38.3% | Reduced |
| Coatue Management LLCSuperinvestorCoatue Management | 9,819,992 | $175.0M | 0.36% | 00.0% | Unchanged |
| Braidwell LP | 8,256,032 | $147.1M | 5.44% | +246,585+3.1% | Added |
| Sixth Street Partners Management Company, L.P. | 7,327,041 | $130.6M | 22.54% | −7,058,358−49.1% | Reduced |
| PointState Capital LP | 6,828,835 | $121.7M | 2.14% | −531,611−7.2% | Reduced |
| JPMorgan Chase & Co | 6,558,514 | $120.2M | 0.01% | +3,098,299+89.5% | Added |
| BlackRock, Inc. | 5,536,798 | $98.7M | 0.00% | +679,686+14.0% | Added |
| T. Rowe Price Investment Management, Inc. | 5,079,141 | $90.5M | 0.06% | −509,116−9.1% | Reduced |
| Vanguard Portfolio Management LLC | 4,844,431 | $86.3M | 0.00% | +1,085,969+28.9% | Added |